Skip to main content

Greenberg Traurig Advised Private Equity Fund Gilde Healthcare on Acquisition of Medical Technology Manufacturer EUROPIN

Greenberg Traurig advised Gilde Healthcare, a specialist healthcare private equity fund, on its acquisition of EUROPIN Group, which is headquartered in Heidelberg, Germany. EUROPIN also has a development and production plant in Trenčín, Slovakia. EUROPIN specializes in the development and manufacturing of customized pen cannulas, lancet needles as well as cannulas for prefilled syringes and pharmaceutical applications. The parties agreed not to disclose the purchase price.

In 2021, Gilde Healthcare had acquired the cannula manufacturer Acti-Med AG, including a Polish subsidiary. According to the investor, the addition of EUROPIN thus represents a major step in forming a leading integrated contract manufacturer for cannulas and cannula systems. It is reported that both companies will operate separately under one roof while retaining both brands individually in the market.

The Greenberg Traurig team comprehensively advised Gilde Healthcare on all legal aspects of the transaction.

Background: Greenberg Traurig already advised the private equity fund on the acquisition of Acti-Med AG. The new instruction on the now completed add-on acquisition underlines the firm's strength in private equity transactions in the health care sector.

About Greenberg Traurig: Greenberg Traurig, LLP has more than 2400 attorneys in 42 locations in the United States, Europe, Latin America, Asia, and the Middle East. The firm, often recognized for its focus on philanthropic giving, innovation, diversity, and pro bono, reported gross revenue of over $2 Billion for FY 2021. The firm is consistently among the top firms on the Am Law 100, Am Law Global 100, NLJ 250, and Law360 (US) 400. On the debut 2022 Law360 Pulse Leaderboard, it is a Top 15 firm. Greenberg Traurig is Mansfield Rule 4.0 Certified Plus by The Diversity Lab and net carbon neutral with respect to its office energy usage. Web: